EpicentRx, Inc.

📍 La Jolla, United States👥 20 employees💰 Last funded Mar 2019
Biotechnology Research🌐 epicentrx.com
Website LinkedIn
EpicentRx is an innovation-driven clinical-stage drug and device company that puts the emphasis on “ease” - ease of treatment, ease of side effects, and ease of symptoms during the treatment of a range of diseases including lung cancer, and head and neck cancer, and different inflammatory disorders for which the company has received several grants and orphan designations. The lead device is called the eLOOP and the lead therapies are the direct NLRP3 inhibitor, nibrozetone (RRx-001), and the TGF-β trap-enhanced oncolytic adenovirus, AdAPT-001, in Phase 3, and Phase 2 clinical trials, respectively.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in EpicentRx, Inc.?
EpicentRx, Inc. has 1 investors on record on gritt.io.
When did EpicentRx, Inc. last raise funding?
The most recent investment in EpicentRx, Inc. recorded on gritt.io was in March 2019.
What industry is EpicentRx, Inc. in?
EpicentRx, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is EpicentRx, Inc. based?
EpicentRx, Inc. is headquartered in La Jolla, United States.